Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: Liabilities and Stockholders’ Equity

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Regeneron Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Accounts payable 418,100  218,200  178,183  134,984  140,962 
Accrued payroll and related costs 344,400  261,800  191,825  153,086  133,223 
Accrued clinical trial expense 142,700  142,200  120,891  91,753  88,297 
Accrued sales-related charges, deductions, and royalties 249,000  182,700  194,542  159,985  195,986 
Income taxes payable 49,400  20,800  227  235,776  — 
Other accrued expenses and liabilities 301,300  164,600  129,677  104,690  86,616 
Accrued expenses and other current liabilities 1,086,800  772,100  637,162  745,290  504,122 
Finance lease liabilities, current portion —  —  —  129,557  1,789 
Deferred revenue from Sanofi, current portion 395,500  246,700  177,746  115,267  101,573 
Deferred revenue, other, current portion 196,200  205,800  142,392  116,397  51,914 
Convertible senior notes, current portion —  —  —  —  10,802 
Current liabilities 2,096,600  1,442,800  1,135,483  1,241,495  811,162 
Finance lease liabilities, excluding current portion 713,900  708,500  703,453  351,569  362,919 
Deferred revenue from Sanofi 509,700  279,300  379,936  503,474  582,664 
Deferred revenue, other 109,300  184,900  249,263  327,298  82,015 
Other noncurrent liabilities 286,000  361,700  152,073  100,385  115,535 
Noncurrent liabilities 1,618,900  1,534,400  1,484,725  1,282,726  1,143,133 
Total liabilities 3,715,500  2,977,200  2,620,208  2,524,221  1,954,295 
Preferred Stock, $.01 par value; issued and outstanding - none —  —  —  —  — 
Class A Stock, convertible, $.001 par value —  —  2  2  2 
Common Stock, $.001 par value 100  100  110  108  106 
Additional paid-in capital 4,428,600  3,911,600  3,512,833  3,029,993  3,099,526 
Retained earnings 7,379,800  5,254,300  2,946,733  1,748,222  852,700 
Accumulated other comprehensive income (loss) 21,100  (12,300) 640  (12,840) 8,572 
Treasury Stock, at cost (739,900) (396,400) (316,240) (316,240) (306,069)
Stockholders’ equity 11,089,700  8,757,300  6,144,078  4,449,245  3,654,837 
Total liabilities and stockholders’ equity 14,805,200  11,734,500  8,764,286  6,973,466  5,609,132 

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc.’s current liabilities increased from 2017 to 2018 and from 2018 to 2019.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent liabilities increased from 2017 to 2018 and from 2018 to 2019.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc.’s total liabilities increased from 2017 to 2018 and from 2018 to 2019.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc.’s stockholders’ equity increased from 2017 to 2018 and from 2018 to 2019.